📝 At #ICML18, the Lymphoma Hub symposium “Customizing therapy for MCL” was chaired by Gilles Salles, featuring presentations from Julie Vose, Wojciech Jurczak, and Michael Wang and concluding with an interactive Q&A session.

Learn more: https://loom.ly/5348JN4
#Lymphoma #lymsm #MedEd

At #ICML18, Alexey Danilov of @cityofhope.bsky.social shared the promising results of a Phase I study evaluating bexobrutideg, a BTK degrader, in R/R CLL resistant to BTK inhibitors.

Watch the interview here:

🎥 buff.ly/cHVydMw

#CLLsm #Leusm #CTSM #TrialUpdate #HemOnc #BloodSky #HemeSky #MedSky

Stathis et al - feasibility of PET & ctDNA response adaptation in 1L DLBCL.
• operationally deliverable with ctDNA turnaround median 9d
• low rate PET+ and ctDNA+ at interim
• assessing whether acala addition benefits those with Myd88 &/or CD79b mutns
SAKK38/19 trial #ICML18

@dgermain21.bsky.social - fantastic work on LymphomaMAPs (microenv of DLBCL) looking at prognosis of CAR-T therapy. Showed that TEX archetype associated with signif worse outcome. Assoc with
• exhausted T-cells
• super-activated macrophages.
#ICML18